



Claim 1. (Currently Amended) A compound of formula I






or a pharmaceutically acceptable salt thereof wherein:

A is a structure i, ii, iii, or iv



B is



W is $\text{NHC}(=\text{X})\text{R}_1$, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is $\text{S}(=\text{O})(=\text{N}-\text{R}_5)$;

R_1 is

- (a) H,
- (b) NH_2 ,
- (c) $\text{NHC}_{1-4}\text{alkyl}$,
- (d) $\text{C}_{1-4}\text{alkyl}$,

- (e) C₂₋₄alkenyl,
- (f) OC₁₋₄alkyl,
- (g) SC₁₋₄alkyl, or
- (h) (CH₂)_p C₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (c) C(=O)C₁₋₄alkyl,
- (d) C(=O)OC₁₋₄alkyl,
- (e) C(=O)NHR₆, or
- (f) C(=S)NHR₆;

R₆ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, ~~CF₃, CH₃~~, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇;

at each occurrence of phenyl in R₅, the phenyl is optionally substituted with CF₃ and CH₃ in addition to one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;


p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3

Claim 2. (Previously Amended) A compound of claim 1 having the formula IA:



IA.

Claim 3. (Original) A compound of claim 2 wherein R₁ is C₁₋₄alkyl.

Claim 4. (Original) A compound of claim 2 wherein R₁ is ethyl.

Claim 5. (Original) A compound of claim 2 wherein R₁ is methyl.

Claim 6. (Original) A compound of claim 2 wherein R₁ is C₃₋₆cycloalkyl.

Claim 7. (Original) A compound of claim 2 wherein R₁ is cyclopropyl.

Claim 8. (Currently Amended) A compound of claim 2, 3, 4, 5, 6, or 7 wherein X is sulfur atom.

Claim 9. (Currently Amended) A compound of claim 2, 3, 4, 5, 6, or 7 wherein X oxygen atom.


Claim 10. (Original) A compound of claim 8 wherein one of R₂ and R₃ is H, the other one is F.

Claim 11. (Original) A compound of claim 9 wherein one of R₂ and R₃ is H, the other one is F.

Claim 12. (Original) A compound of claim 8 wherein R_4 is H.

Claim 13. (Original) A compound of claim 9 wherein R_4 is H.


Claim 14. (Original) A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.


Claim 15. (Canceled).

Claim 16. (Previously Amended) A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

Claim 17. (Original) A compound of claim 9 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

Claims 18-21. (Canceled).

Claim 22. (Original) A compound of claim 14 wherein R_5 is $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, $C(=O)NH_2$, or $C(=O)NHC_{1-4}alkyl$.

Claim 23. (Original) A compound of claim 22 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

Claim 24. (Original) A compound of claim 14 wherein R_5 is $C(=O)CH_3$.

Claim 25. (Original) A compound of claim 14 wherein R_5 is $C(=O)OCH_3$.

Claims 26-29. (Canceled).

Claim 30. (Original) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula I as shown in claim 1.

Claim 31. (Original) The method of claim 30 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

Claim 32. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

Claim 33. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

Claim 34. (Original) A method for treating microbial infections of claim 30 wherein the infection is skin infection.

Claim 35. (Original) A method for treating microbial infections of claim 30 wherein the infection is eye infection.

Claim 36. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 37. (Canceled)

Claim 38. (Original) A compound of claim 16 wherein R_5 is $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, $C(=O)NH_2$, or $C(=O)NHC_{1-4}alkyl$.

Claim 39. (Original) A compound of claim 38 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

Claim 40. (Original) A compound of claim 16 wherein R_5 is $C(=O)CH_3$.

Claim 41. (Original) A compound of claim 16 wherein R_5 is $C(=O)OCH_3$.

Claim 42. (Original) A compound of claim 17 wherein R_5 is $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, $C(=O)NH_2$, or $C(=O)NHC_{1-4}alkyl$.

Claim 43. (Original) A compound of claim 42 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

Claim 44. (Original) A compound of claim 17 wherein R_5 is $C(=O)CH_3$.

Claim 45. (Original) A compound of claim 17 wherein R_5 is $C(=O)OCH_3$.

Claim 46. (Previously Amended) A compound of claim 2 which is

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-{{(methylamino)carbonyl}imino}-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanethioamide, *Z*-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(ethoxycarbonyl)methyl]imino)-1-oxido-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[[[(4-nitrophenyl)amino]carbonyl]imino]-1-oxido-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxido-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(aminocarbonyl)methyl]imino]-1-oxido-1λ⁴-thiopyran-4-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-(((5S)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ⁴, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide;


N-(((5S)-3-{3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxido-1λ⁴, 4-thiazinan-4-yl)phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanecarbothioamide ;

N-(((5S)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxido-1λ⁴-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl) cyclopropanecarbothioamide, Z-isomer;

N-(((5S)-3-{3-fluoro-4-[1-[(phenylmethoxy)carbonyl]imino]-1-oxido-1λ⁴-thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, Z-isomer; or

N-((5S)-3-[3-fluoro-4-(1-[[[(benzylamino)carbonyl]imino]-1-oxido-1λ⁴-thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, Z-isomer.


Claim 47. (Currently amended) 4- A compound of formula II




II

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



B is




W is $\text{NHC}(=\text{X})\text{R}_1$, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is $\text{S}(=\text{O})(=\text{N}-\text{R}_5)$ and the B ring has the following stereochemistry



R_1 is

- (a) H,
- (b) NH_2 ,
- (c) $\text{NHC}_{1-4}\text{alkyl}$,
- (d) $\text{C}_{1-4}\text{alkyl}$,
- (e) $\text{C}_{2-4}\text{alkenyl}$,
- (f) $\text{OC}_{1-4}\text{alkyl}$,
- (g) $\text{SC}_{1-4}\text{alkyl}$, or
- (h) $(\text{CH}_2)_p \text{C}_{3-6}\text{cycloalkyl}$;

at each occurrence, alkyl or cycloalkyl in R_1 is optionally substituted with one or more F, Cl or CN;

R_2 and R_3 are independently H, F, Cl, methyl or ethyl;

R_4 is H, CH_3 , or F;

R_5 is

- (a) H,
- (b) C_{1-4} alkyl,
- (c) $C(=O)C_{1-4}$ alkyl,
- (d) $C(=O)OC_{1-4}$ alkyl,
- (e) $C(=O)NHR_6$, or
- (f) $C(=S)NHR_6$;

R_6 is H, C_{1-4} alkyl, or phenyl;

at each occurrence, alkyl in R_5 and R_6 is optionally substituted with one or more halo, CN, NO_2 , phenyl, C_{3-6} cycloalkyl, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, NR_7R_7 , oxo, or oxime;

R_7 is H, C_{1-4} alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, ~~CF_3 , CH_3~~ , CN, NO_2 , phenyl, C_{3-6} cycloalkyl, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7 ;

at each occurrence of phenyl in R_5 the phenyl is optionally substituted with CF_3 and CH_3 in addition to one or more halo, CN, NO_2 , phenyl, C_{3-6} cycloalkyl, OR_7 , $C(=O)R_7$, $OC(=O)R_7$, $C(=O)OR_7$, $S(=O)_mR_7$, $S(=O)_mNR_7R_7$, $NR_7SO_2R_7$, $NR_7SO_2NR_7R_7$, $NR_7C(=O)R_7$, $C(=O)NR_7R_7$, or NR_7R_7 ;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2;

and ~~====~~ in structure iii is either a double bond or a single bond.

Claim 48. (Previously Added) The compound of claim 47 wherein R₁ is C₁₋₄alkyl.

Claim 49. (Previously Added) The compound of claim 47 wherein R₁ is ethyl.

Claim 50. (Previously Added) The compound of claim 47 wherein R₁ is methyl.

Claim 51. (Previously Added) The compound of claim 47 wherein R₁ is C₃₋₆cycloalkyl.

Claim 52. (Previously Added and Amended) The compound of claim 47 wherein R₁ is cyclopropyl.

Claim 53. (Previously Added) The compound of claim 47 wherein X is sulfur atom.

Claim 54. (Previously Added) The compound of claim 47 wherein X oxygen atom.

Claim 55. (Previously Added) The compound of claim 53 wherein one of R₂ and R₃ is H, the other one is F.

Claim 56. (Previously Added) The compound of claim 54 wherein one of R₂ and R₃ is H, the other one is F.

Claim 57. (Previously Added) The compound of claim 47 wherein R₅ is H.

Claim 58. (Previously Added) The compound of claim 47 wherein R₅ is C₁₋₄alkyl, optionally substituted with OH; or C₁₋₄alkyl substituted with C(=O)NHC₁₋₄alkyl, C(=O)NH₂ or phenyl; wherein the phenyl is optionally substituted with OH, methyl, NO₂, CF₃, or CN.

Claim 59. (Previously Added) The compound of claim 47 wherein R₅ is CH₃, or ethyl.

Claim 60. (Previously Added) The compound of claim 47 wherein R₅ is C₁₋₄alkyl substituted with phenyl wherein the phenyl is optionally substituted with NO₂.

Claim 61. (Previously Added) The compound of claim 47 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

Claim 62. (Previously Added) The compound of claim 47 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.

Claim 63. (Previously Added) The compound of claim 47 wherein R₅ is C(=O)CH₃.

Claim 64. (Previously Added and Amended) The compound of claim 47 wherein R₅ is C(=O)OCH₃.

Claim 65. (Previously Added and Amended) A compound of claim 47 which is

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanethioamide (Z)-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, Z-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(methyylimino)-1-oxido-1,3-oxazolidin-5-yl)methyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(ethylimino)-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(phenylmethyl)imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(3-phenylpropyl)imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(methylamino)carbonyl]imino)-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[[ethoxycarbonyl)methyl]imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-(1-[[[(4-nitrophenyl)amino]carbonyl]imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer ;

N-((5S)-3-[3-fluoro-4-[1-[(aminocarbonyl)imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[[aminocarbonyl)methyl]imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl)-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-[(2-hydroxyethyl)imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, Z-isomer;

N-((5S)-3-[3-fluoro-4-[1-(methylimino)-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanecarbothioamide, Z-isomer;

N-(((5S)-3-{3-fluoro-4-[1-[(methoxycarbonyl)imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanecarbothioamide, Z-isomer;

N-(((5S)-3-{3-fluoro-4-[1-[(phenylmethoxy)carbonyl]imino]-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, Z-isomer; or

N-({(5*S*)-3-[3-fluoro-4-(1-{{(benzylamino)carbonyl}imino}-1-oxidohexahydro-1 λ^4 -thiopyran-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, *Z*-isomer.

Claim 66. (Currently Amended) A method for treating microbial infections comprising:
administering to a mammal in need thereof an effective amount of a compound of formula II as
shown in claim 47.